



## Curtis R. Chong, MD, PhD, MPhil, FACP

Clinical Assistant Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Clinic**

440 Broadway St Pav B35M

3rd Fl MC 6232

Redwood City, CA 94063

Tel (650) 498-6000      Fax (650) 368-0254

### Bio

---

#### BIO

Dr. Chong was recruited to Stanford from the Memorial Sloan Kettering (MSK) Cancer Center, where he led MSK's launch of the early drug development and immunotherapy clinical trials program in New Jersey. At MSK, Dr. Chong was a member of the gastrointestinal oncology service and was one of two MSK physicians in New Jersey who specialized in treating melanoma. Prior to joining MSK, Dr. Chong was a member of the thoracic oncology service at the Dana-Farber Cancer Institute and an attending physician at the Massachusetts General Hospital and Brigham and Women's Hospital, all affiliates of Harvard Medical School.

Dr. Chong completed his categorical residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, his oncology fellowship at the Dana-Farber Cancer Institute, and is board-certified in internal medicine and medical oncology. He has received research support from the American Society of Clinical Oncology (Young Investigator Award), Uniting Against Lung Cancer, and the American Cancer Society. Dr. Chong has been published in the New England Journal of Medicine, Nature, Nature Medicine, Nature Chemical Biology, JAMA Oncology, and his research on drug discovery has been featured in the New York Times and Popular Science.

Born and raised in Honolulu where he attended public schools, Dr. Chong sang in the Honolulu Boy Choir, and was the 1993 Honolulu Star Bulletin Newspaper Boy of the Year. He received his A.B. in biochemical sciences from Harvard University magna cum laude followed by an M.Phil. in Chemistry with Sir Alan Fersht at the University of Cambridge (Emmanuel College). He then received his MD and PhD in pharmacology from The Johns Hopkins University School of Medicine.

An intrepid traveler and avid long-distance runner, Dr. Chong has visited 54 countries and completed 126 marathons in all 50 states, 18 countries, and 6 on continents.

#### CLINICAL FOCUS

- Medical Oncology

## **ACADEMIC APPOINTMENTS**

- Clinical Assistant Professor, Medicine - Oncology

## **ADMINISTRATIVE APPOINTMENTS**

- Ambulatory CODE Team Leader, Dana-Farber Cancer Institute, (2014-2015)
- Assistant Attending Physician, Memorial Sloan-Kettering Cancer Center, (2017- present)
- Assistant in Medicine, Massachusetts General Hospital, (2015-2017)
- Assistant Professor, Weill Cornell Medical College, (2017- present)
- Attending Physician, Brigham and Women's Hospital and Dana-Farber Cancer Institute, (2015-2016)
- Attending Physician, Kaiser Permanente, San Rafael, California, (2016-2018)
- Attending Physician, VA Boston, (2017-2017)
- Bone Marrow Harvest Team, Dana-Farber Cancer Institute, (2013-2014)
- Clinical Fellow in Medicine, Harvard Medical School, (2008-2015)
- Director of Phase I and Immunotherapy Clinical Trials Program, Memorial Sloan-Kettering Cancer Center, New Jersey, (2017- present)
- Hospitalist, Massachusetts General Hospital, (2015-2017)
- Inpatient Oncology Hospitalist, Women's Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, (2014-2014)
- Instructor in Medicine, Harvard Medical School, (2015-2017)
- Internal Medicine Intern, Massachusetts General Hospital, (2008-2009)
- Internal Medicine Resident, Massachusetts General Hospital, (2009-2011)
- Medical Oncology Fellow, Dana-Farber Cancer Institute, (2011-2015)
- Moonlighting Physician, Hospital Medicine Group, Massachusetts General Hospital, (2010-2011)

## **HONORS AND AWARDS**

- Bial Award Diploma of Distinction, Bial Foundation for Medical Research and Portuguese Republic (2011)
- Breast Cancer predoctoral fellowship, Office of the Congressionally Directed Medical Research Programs (2003-2006)
- Fellow, American College of Physicians (2014)
- Grand prize (\$205,000), Rice University (2007)
- Harold M. Weintraub Graduate Student Award, University of Washington (2006)
- Honorable mention, Thomas Hoopes Prize, Harvard University (1998)
- John Harvard Scholarship, Harvard University (1997-1998)
- Michael Shano Young Investigator Award, The Johns Hopkins University School of Medicine (2007)
- Rotary Foundation Ambassadorial Scholar, Rotary International (1998-1999)
- Young Investigator Award, American Society for Clinical Oncology (2013)

## **PROFESSIONAL EDUCATION**

- Board Certification: Internal Medicine, American Board of Internal Medicine (2023)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2015)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2015) MA
- Residency: Massachusetts General Hospital Internal Medicine Residency (2011) MA
- Medical Education: Johns Hopkins University School of Medicine (2008) MD
- M.Phil., University of Cambridge , Chemistry (1999)

- AB, Harvard University , Biochemical Sciences (1998)

## Publications

---

### PUBLICATIONS

- **A Case of Adenocarcinoma of Unknown Primary Site in a Lynch Syndrome Patient Responds to Ipilimumab/Nivolumab** *Case Reports in Gastrointestinal Medicine*  
Kirmani, N., Jayapal, P., Ladabaum, U., Bingham, D., Chong, C. R.  
2026; 3296346: 5
- **Bath** *JAMA ONCOLOGY*  
Chong, C. R.  
2017; 3 (10): 1308
- **Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer** *CLINICAL CANCER RESEARCH*  
Chong, C. R., Bahcall, M., Capelletti, M., Kosaka, T., Ercan, D., Sim, T., Sholl, L. M., Nishino, M., Johnson, B. E., Gray, N. S., Janne, P. A.  
2017; 23 (1): 204–13
- **Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis**  
John, S. F., Aniemeké, E., Ha, N. P., Chong, C. R., Gu, P., Zhou, J., Zhang, Y., Graviss, E. A., Liu, J. O., Olaleye, O. A.  
CHURCHILL LIVINGSTONE.2016: S73–S77
- **Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer** *CANCER IMMUNOLOGY RESEARCH*  
Nishino, M., Chambers, E. S., Chong, C. R., Ramaiya, N. H., Gray, S. W., Marcoux, J., Hatabu, H., Janne, P. A., Hodi, F., Awad, M. M.  
2016; 4 (4): 289–93
- **Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation** *ONCOTARGET*  
Lee, H., Kim, H., Kim, E., Park, P., Dong, S., Choi, T., Kim, H., Chong, C. R., Liu, J. O., Chen, J., Ambinder, R. F., Hayward, S., Park, et al  
2015; 6 (31): 31018–29
- **Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors** *LUNG CANCER*  
Chong, C. R., Wirth, L. J., Nishino, M., Chen, A. B., Sholl, L. M., Kulke, M. H., McNamee, C. J., Jaenne, P. A., Johnson, B. E.  
2014; 86 (2): 241–46
- **The quest to overcome resistance to EGFR-targeted therapies in cancer** *NATURE MEDICINE*  
Chong, C. R., Jaenne, P. A.  
2013; 19 (11): 1389–1400
- **Substituted oxines inhibit endothelial cell proliferation and angiogenesis** *ORGANIC & BIOMOLECULAR CHEMISTRY*  
Bhat, S., Shim, J., Zhang, F., Chong, C., Liu, J. O.  
2012; 10 (15): 2979–92
- **Characterization of cloiquinol and analogues as novel inhibitors of methionine aminopeptidases from Mycobacterium tuberculosis** *TUBERCULOSIS*  
Olaleye, O., Raghunand, T. R., Bhat, S., Chong, C., Gu, P., Zhou, J., Zhang, Y., Bishai, W. R., Liu, J. O.  
2011; 91: S61–S65
- **A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment** *CANCER DISCOVERY*  
Platz, E. A., Yegnasubramanian, S., Liu, J. O., Chong, C. R., Shim, J., Kenfield, S. A., Stampfer, M. J., Willett, W. C., Giovannucci, E., Nelson, W. G.  
2011; 1 (1): 68–77
- **Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*  
Shim, J., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H. C., Dhara, S., Han, K., Chong, C. R., Pomper, M. G., So, A., Liu, J. O.  
2010; 102 (24): 1855–73
- **An Unnecessary Death in Zambia** *AMERICAN JOURNAL OF MEDICINE*  
Chong, C. R.  
2010; 123 (7): 669

- **Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth** *CANCER CELL*  
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., Chong, C. R., Chang, K. S., Fereshteh, M., Gardner, D., Reya, T., Liu, J. O., Epstein, et al  
2010; 17 (4): 388-399
- **Itraconazole as a novel Hedgehog pathway antagonist in cancer therapy**  
Kim, J., Gong, R., Lee, J., Chong, C., Clemons, K., Liu, J., Stevens, D., Beachy, P.  
AMER ASSOC CANCER RESEARCH.2009
- **Mysterious Metformin** *ONCOLOGIST*  
Chong, C. R., Chabner, B. A.  
2009; 14 (12): 1178-81
- **Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes** *PLOS ONE*  
Ren, Y. R., Pan, F., Parvez, S., Fleig, A., Chong, C. R., Xu, J., Dang, Y., Zhang, J., Jiang, H., Penner, R., Liu, J. O.  
2008; 3 (12): e4009
- **Efficacy of pyrvinium pamoate against *Cryptosporidium parvum* infection in vitro and in a neonatal mouse model** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Downey, A. S., Chong, C. R., Graczyk, T. K., Sullivan, D. J.  
2008; 52 (9): 3106-12
- **Idiopathic Infantile Arterial Calcification: The Spectrum of Clinical Presentations** *PEDIATRIC AND DEVELOPMENTAL PATHOLOGY*  
Chong, C. R., Hutchins, G. M.  
2008; 11 (5): 405-15
- **Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister *Mycobacterium tuberculosis*** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Byrne, S. T., Gu, P., Zhou, H., Denkin, S. M., Chong, C., Sullivan, D., Liu, J. O., Zhang, Y.  
2007; 51 (12): 4495-97
- **Catalysis of zinc transfer by D-penicillamine to secondary chelators** *JOURNAL OF MEDICINAL CHEMISTRY*  
Chong, C. R., Auld, D. S.  
2007; 50 (22): 5524-27
- **New uses for old drugs** *NATURE*  
Chong, C. R., Sullivan, D. J.  
2007; 448 (7154): 645-46
- **Brief report - The HBV drug entecavir - Effects on HIV-1 replication and resistance** *NEW ENGLAND JOURNAL OF MEDICINE*  
McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., Chong, C. R., Liu, J. O., Siliciano, et al  
2007; 356 (25): 2614-21
- **Inhibition of angiogenesis by the antifungal drug itraconazole** *ACS CHEMICAL BIOLOGY*  
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., Liu, J. O.  
2007; 2 (4): 263-70
- **Inhibitors of *Plasmodium falciparum* methionine aminopeptidase 1b possess antimalarial activity** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Chen, X., Chong, C. R., Shi, L., Yoshimoto, T., Sullivan, D. J., Liu, J. O.  
2006; 103 (39): 14548-53
- **Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo** *JOURNAL OF MEDICINAL CHEMISTRY*  
Lu, J., Chong, C. R., Hu, X., Liu, J. O.  
2006; 49 (19): 5645-48
- **A clinical drug library screen identifies astemizole as an antimalarial agent** *NATURE CHEMICAL BIOLOGY*  
Chong, C. R., Chen, X., Shi, L., O Liu, J., Sullivan, D. J.  
2006; 2 (8): 415-16

- **Reading dynamic kinase activity in living cells for high-throughput screening** *ACS CHEMICAL BIOLOGY*  
Allen, M. D., DiPilato, L. M., Rahdar, M., Ren, Y. R., Chong, C., Liu, J. O., Zhang, J.  
2006; 1 (6): 371–76
- **Identification of inosine monophosphate dehydrogenase as an anti-angiogenic drug target**  
Chong, C., Pan, F., Sullivan, D. J., Liu, J. O.  
FEDERATION AMER SOC EXP BIOL.2005: A276
- **Copper pathways in Plasmodium falciparum infected erythrocytes indicate an efflux role for the copper P-ATPase** *BIOCHEMICAL JOURNAL*  
Rasoloson, D., Shi, L. R., Chong, C. R., Kafsack, B. F., Sullivan, D. J.  
2004; 381: 803–11
- **Inhibition of heme crystal growth by antimalarials and other compounds: implications for drug discovery** *BIOCHEMICAL PHARMACOLOGY*  
Chong, C. R., Sullivan, D. J.  
2003; 66 (11): 2201–12
- **Crystal structure of carboxypeptidase A complexed with D-cysteine at 1.75 angstrom - Inhibitor-induced conformational changes** *BIOCHEMISTRY*  
van Aalten, D. M., Chong, C. R., Joshua-Tor, L.  
2000; 39 (33): 10082–89
- **Inhibition of carboxypeptidase A by D-penicillamine: Mechanism and implications for drug design** *BIOCHEMISTRY*  
Chong, C. R., Auld, D. S.  
2000; 39 (25): 7580–88
- **Hyperglycemia in hummingbirds and its consequences for hemoglobin glycation** *COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY*  
Beuchat, C. A., Chong, C. R.  
1998; 120 (3): 409–16